Tomofumi Osako
Overview
Explore the profile of Tomofumi Osako including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takahashi M, Osako T, Yasojima H, Inoue K, Kawashima M, Maeda H, et al.
Breast Cancer
. 2023 Oct;
31(1):53-62.
PMID: 37882974
Background: An open-label, single-arm, Japanese phase 2 study (J-Ph2) investigated the efficacy and safety of first-line (1L) palbociclib (PAL) + letrozole (LET) in postmenopausal Japanese women with ER+/HER2- advanced breast...
2.
Takano T, Ito M, Kadoya T, Osako T, Aruga T, Masuda N, et al.
Cancer Med
. 2023 Oct;
12(20):20242-20250.
PMID: 37824431
Introduction: Pegfilgrastim is indicated to decrease the incidence of chemotherapy-induced febrile neutropenia. It is the first granulocyte-colony stimulating factor approved for prophylactic use regardless of carcinoma type and is marketed...
3.
Mizoguchi K, Kawaji H, Kai M, Morisaki T, Hayashi S, Takao Y, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760424
Tumor-infiltrating lymphocytes in the tumor microenvironment are important in the treatment of triple-negative breast cancer (TNBC). Cytotoxic T cells produce cytokines and cytotoxic factors, such as perforin and granzyme, which...
4.
Nishimura R, Osako T, Okumura Y, Nakano M, Ohtsuka H, Fujisue M, et al.
Oncol Lett
. 2022 Jun;
24(2):245.
PMID: 35761943
Lymphovascular invasion (LVI) is associated with a poor outcome in breast cancer. The purpose of the present study was to evaluate the clinical significance of LVI in primary breast cancer...
5.
Nishimura R, Osako T, Okumura Y, Nakano M, Otsuka H, Fujisue M, et al.
J Clin Med
. 2022 May;
11(9).
PMID: 35566456
Background: Triple negative breast cancer (TNBC) is a subtype of breast cancer which lacks hormone receptor (HR) expression and HER2 gene amplification and is the most aggressive subtype, with a...
6.
Takahashi M, Ohtani S, Nagai S, Takashima S, Yamaguchi M, Tsuneizumi M, et al.
Breast Cancer Res Treat
. 2020 Sep;
185(1):125-134.
PMID: 32920732
Purpose: In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free...
7.
Kurata K, Kubo M, Kai M, Mori H, Kawaji H, Kaneshiro K, et al.
Breast Cancer
. 2020 Jan;
27(3):490-498.
PMID: 31907878
Background: It is important to identify biomarkers for triple-negative breast cancers (TNBCs). Recently, pembrolizumab, an immune checkpoint inhibitor (ICI) for programmed cell death 1 (PD-1), was approved as a treatment...
8.
Mori H, Kubo M, Kai M, Yamada M, Kurata K, Kawaji H, et al.
Breast Cancer Res Treat
. 2019 May;
176(3):569-577.
PMID: 31069590
Purpose: T-box transcription factor 21 (T-bet), which is the master regulator of effector T-cell activation, is derived by stimulation of T-cell receptors. In this study, we focused on T-bet and...
9.
Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, et al.
Oncol Lett
. 2019 Jan;
17(2):2177-2186.
PMID: 30675282
The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the...
10.
Arima N, Nishimura R, Osako T, Okumura Y, Nakano M, Fujisue M, et al.
Oncol Lett
. 2019 Jan;
17(1):616-622.
PMID: 30655808
Gene profiling has identified at least 4 breast cancer subtypes, including Luminal A, Luminal B, HER2-enriched and basal-like, and immunohistochemistry is used as a guide to determine these subtypes. In...